Professor, Medicine, UCSF School of Medicine
Oncology
Dr. Mark M. Moasser, MD
|
|
Give Review
Mark Moasser works in the field of Oncology. He graduated from Tufts University School of Medicine. Tufts University School of Medicine has a rank of 49 in research and a 52 in primary care He received awards:"CMS Meaningful Use Stage 1 Certification" and "Elected Member". Mark Moasser is a published MD as well. He has 62 publications published. The latest was: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. He is registered with Medicare.
Publications
- The Evolving Landscape of HER2 Targeting in Breast Cancer.
- Chemical probing of HER2-amplified Cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
- Clinical Cancer advances 2015: annual report on progress against Cancer from the american society of clinical oncology.
- Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.
- A multilevel model of postmenopausal breast Cancer incidence.
- Two Dimensions in Targeting HER2.
- An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase.
- Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells.
- HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.
- Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state.
- Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling.
- The structural features of trask that mediate its anti-adhesive functions.
- HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and Cancer therapy.
- Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
- A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid Malignancies.
- The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation.
- Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial Cancers.
- A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast Cancer.
- Cellular mechanisms of resistance to anthracyclines and taxanes in Cancer: intrinsic and acquired.
- Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.
- A phase II trial of gemcitabine in patients with metastatic breast Cancer previously treated with an anthracycline and taxane.
- Phase II study of celecoxib and trastuzumab in metastatic breast Cancer patients who have progressed after prior trastuzumab-based treatments.
- S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors.
- Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive ph...
- A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
- A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast Cancer.
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast Cancer.
- A chemical screen in diverse breast Cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
- Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of ...
- Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast Cancer.
- A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast Cancer.
- A prospective, longitudinal study of the functional status and quality of life of older patients with breast Cancer receiving adjuvant chemotherapy.
- Cognitive function of older patients receiving adjuvant chemotherapy for breast Cancer: a pilot prospective longitudinal study.
- Effect of adjuvant breast Cancer chemotherapy on cognitive function from the older patient''s perspective.
- Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal Carcinoma cell line.
- Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with Analysis of efficacy by HER2 immunophenotype and gene amplification.
- Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast Cancer cells.
- Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
- Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.
- Derivation and characterization of retinoid-resistant human embryonal Carcinoma cells.
- all-trans retinoic acid for treating germ cell Tumors. In vitro activity and results of a phase II trial.
- Growth suppression of transformed human bronchial epithelial cells by all-trans-retinoic acid occurs through specific retinoid receptors.
- Response and resistance to retinoic acid are mediated through the retinoic acid nuclear receptor gamma in human teratoCarcinomas.
- Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
- Overexpression of the retinoic acid receptor gamma directly induces terminal differentiation of human embryonal Carcinoma cells.
- Adhesion signaling by a novel mitotic substrate of src kinases.
- Targeting HER proteins in Cancer therapy and the role of the non-target HER3.
- Targeting the function of the HER2 oncogene in human Cancer therapeutics.
- The oncogene HER2: its signaling and transforming functions and its role in human Cancer pathogenesis.
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
- The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
- Oral gossypol in the treatment of patients with refractory metastatic breast Cancer: a phase I/II clinical trial.
- The epidermal growth factor receptor family: biology driving targeted therapeutics.
- The HER family and Cancer: emerging molecular mechanisms and therapeutic targets.
- HER-2-directed, small-molecule antagonists.
- The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast Cancer.
- MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a Breast tumor xenograft model.
- The role of HER3, the unpretentious member of the HER family, in Cancer biology and Cancer therapeutics.
- A tumor-suppressing function in the epithelial adhesion protein Trask.
- Effective treatment of HER2-amplified breast Cancer by targeting HER3 and β1 integrin.
- A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor Malignancies.
Schools
Tufts Univ Sch Of Med
Cornell Ny Hospital
Meml Sloan Kettering Canc Center
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Basic HMO
- Choice Plus POS II
- Vitalidad Plus California Con Aetna
- Blue Card PPO
- CaliforniaCare HMO
- Blue Cross Blue Shield of California PPO
- Select Plus HMO
- Access Plus Savenet
- Enhanced Exclusive for Small Business HMO
- Local Access Plus HMO
- Brown & Toland Physicians
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Coventry Health Care
- Delta Health System
- First Health (Coventry Health Care) PPO
- Blue & Gold HMO
- Employer Group HMO
- WholeCare Network HMO
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Elected Member
Education
-
Memorial Sloan-Kettering Cancer Center -
New York Presbyterian Hospital - Cornell Campus -
Tufts University School of Medicine
Hospital
-
San Francisco General Hospital and Trauma Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1417911751 | |
| NPPES Provider LastName | MOASSER | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 941153010 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 292.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 27.0 | |
| Percent Opioid Claims | 9.25 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417911751 |
| Last Name Of The Provider | MOASSER |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Garrett A. Smith, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Collin M. Blakely, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rupali K. Nabar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alan B. Newman, MD |
|
|
Dr. Andrew H. Ko, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. James M. Kahn, DO |
|
|
Dr. Daniel W. Sherbenou, MD
This Doctor is OpenDoctor Recommended.
|